Two cases decided over the last three months have added California[1] and Massachusetts[2] to the list of minority states that hold brand name manufacturers of drugs (“Brand Manufacturers”) liable under state “failure to warn” laws when sued by patients that exclusively used a generic version of the Brand Manufacturer’s drug. These cases follow the US Supreme Court decision in PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011) (“PLIVA”), which held that generic drug manufacturers cannot be held liable for failure to update the safety label of a drug or biologic in ...
Blog Editors
Recent Updates
- Navigating the Legal Risks of Consumer Protection Claims in Healthcare
- Oregon SB 951, Regulating the Corporate Practice of Medicine, Is Signed into Law—But Changes May Be in the Works Already
- CMS Doubles Down on Medicare Advantage Recoupment: Announces Aggressive RADV Strategy to Reclaim Billions
- HealthBench: Advancing the Standard for Evaluating AI in Health Care
- What Health Care Lawyers and Professionals Need to Know About Emerging Employee Benefit Issues